Marrone Bio Innovations, Inc. provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation. The company's products include Regalia, a plant extract-based fungicidal biopesticide for plant disease control and plant health; and Grandevo, a bioinsecticide for insect and mite control to the growers of specialty crops, such as grapes, citrus, tomatoes, vegetables, nuts, leafy greens, and ornamental plants. It also provides Zequanox, a biomolluscicide that controls invasive mussels, which cause infrastructure and ecological damage primarily to power and industrial companies; and Venerate, a bioinsecticide, which controls chewing and sucking insects and mites, as well as flies and plant parasitic nematodes. In addition, the company offers Haven, an sun protectant product that reduces plant stress and dehydration; and Majestene and Zelto, a bionematicide to control soil-dwelling nematodes by preventing and reducing root galls, as well as reducing adult reproduction and egg hatch. Further, it provides Stargus and Amplitude, a biofungicide for improving plant health. Marrone Bio Innovations, Inc. provides its products directly through sales force, as well as through distributors. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was founded in 2006 and is headquartered in Davis, California.
Industry, Sector and Symbol
Industry Agricultural chemicals
Sub-IndustryN/A
SectorBasic Materials
SymbolNASDAQ:MBII
CUSIPN/A
Phone530-750-2800
Debt
Debt-to-Equity Ratio1.40
Current Ratio2.63
Quick Ratio1.76
Price-To-Earnings
Trailing P/E Ratio-1.61
Forward P/E Ratio-10.75
P/E GrowthN/A
Sales & Book Value
Annual Sales$18.17 million
Price / Sales9.66
Cash FlowN/A
Price / CashN/A
Book Value($1.62) per share
Price / Book-1.06
Profitability
EPS (Most Recent Fiscal Year)($1.07)
Net Income$-30,920,000.00
Net Margins-144.82%
Return on EquityN/A
Return on Assets-62.44%
Miscellaneous
Employees103
Outstanding Shares102,090,000
Marrone Bio Innovations (NASDAQ:MBII) Frequently Asked Questions
What is Marrone Bio Innovations' stock symbol?
Marrone Bio Innovations trades on the NASDAQ under the ticker symbol "MBII."
How were Marrone Bio Innovations' earnings last quarter?
Marrone Bio Innovations Inc (NASDAQ:MBII) announced its quarterly earnings results on Thursday, May, 10th. The basic materials company reported ($0.04) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.04). The basic materials company had revenue of $4.32 million for the quarter. View Marrone Bio Innovations' Earnings History.
What price target have analysts set for MBII?
3 brokers have issued 12-month price objectives for Marrone Bio Innovations' shares. Their predictions range from $1.00 to $4.00. On average, they anticipate Marrone Bio Innovations' share price to reach $2.1833 in the next twelve months. View Analyst Ratings for Marrone Bio Innovations.
Who are some of Marrone Bio Innovations' key competitors?
Some companies that are related to Marrone Bio Innovations include American Vanguard (AVD), Calyxt (CLXT), CVR Partners (UAN), Evogene (EVGN), Wynnstay Group (WYN), China Green Agriculture (CGA), SenesTech (SNES), Arcadia Biosciences (RKDA), Eden Research (EDEN), Kiwa Bio-Tech Products Group (KWBT), Bion Environmental Technologies (BNET), Cavitation Technologies (CVAT) and Syngenta (SYT).
Who are Marrone Bio Innovations' key executives?
Marrone Bio Innovations' management team includes the folowing people:
- Dr. Pamela G. Marrone, Founder, CEO & Director (Age 61)
- Mr. James B. Boyd, Pres & CFO (Age 65)
- Ms. Linda V. Moore, Chief Compliance Officer, Gen. Counsel, Exec. VP & Sec. (Age 71)
- Dr. Amit Vasavada Ph.D., Sr. VP of R&D and CTO (Age 63)
- Dr. Timothy B. Johnson, VP of Field Devel. & Technical Services (Age 61)
Has Marrone Bio Innovations been receiving favorable news coverage?
Media headlines about MBII stock have been trending somewhat positive on Thursday, according to Accern Sentiment. The research group scores the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Marrone Bio Innovations earned a news impact score of 0.14 on Accern's scale. They also gave news headlines about the basic materials company an impact score of 46.91 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Marrone Bio Innovations?
Shares of MBII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Marrone Bio Innovations' stock price today?
One share of MBII stock can currently be purchased for approximately $1.72.
How big of a company is Marrone Bio Innovations?
Marrone Bio Innovations has a market capitalization of $185.81 million and generates $18.17 million in revenue each year. The basic materials company earns $-30,920,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Marrone Bio Innovations employs 103 workers across the globe.
How can I contact Marrone Bio Innovations?
Marrone Bio Innovations' mailing address is 1540 Drew Avenue, Davis CA, 95618. The basic materials company can be reached via phone at 530-750-2800 or via email at [email protected]
MarketBeat Community Rating for Marrone Bio Innovations (MBII)
MarketBeat's community ratings are surveys of what our community members think about Marrone Bio Innovations and other stocks. Vote "Outperform" if you believe MBII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBII will underperform the S&P 500 over the long term. You may vote once every thirty days.
